Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat lung cancer: experimental drug enters human testing

NCT ID NCT05275868

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This was an early-stage study testing a new drug called MGY825 in adults with advanced non-small cell lung cancer that had worsened despite standard treatments. The main goals were to find a safe dose and see how well the drug was tolerated. The study also looked for early signs that the drug might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering

    New York, New York, 10017, United States

  • Memorial Sloan Kettering Onc. Dept

    New York, New York, 10017, United States

  • NYU School of Medicine

    New York, New York, 10015, United States

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Madrid, 28050, Spain

  • Novartis Investigative Site

    Geneva, CH 1211, Switzerland

  • Novartis Investigative Site

    Sankt Gallen, 9007, Switzerland

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas, 77030, United States

  • Wash U School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER